348 related articles for article (PubMed ID: 30628768)
21. Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.
Duce JA; Wong BX; Durham H; Devedjian JC; Smith DP; Devos D
Mol Neurodegener; 2017 Jun; 12(1):45. PubMed ID: 28592304
[TBL] [Abstract][Full Text] [Related]
22. Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.
Haj-Yahya M; Fauvet B; Herman-Bachinsky Y; Hejjaoui M; Bavikar SN; Karthikeyan SV; Ciechanover A; Lashuel HA; Brik A
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17726-31. PubMed ID: 24043770
[TBL] [Abstract][Full Text] [Related]
23. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
Wu W; Sung CC; Yu P; Li J; Chung KKK
PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
[TBL] [Abstract][Full Text] [Related]
24. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
[TBL] [Abstract][Full Text] [Related]
25. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125.
Hejjaoui M; Butterfield S; Fauvet B; Vercruysse F; Cui J; Dikiy I; Prudent M; Olschewski D; Zhang Y; Eliezer D; Lashuel HA
J Am Chem Soc; 2012 Mar; 134(11):5196-210. PubMed ID: 22339654
[TBL] [Abstract][Full Text] [Related]
26. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
27. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
[TBL] [Abstract][Full Text] [Related]
28. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
29. The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease.
Battis K; Xiang W; Winkler J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686080
[TBL] [Abstract][Full Text] [Related]
30. α-Synuclein aggregation and modulating factors.
Paleologou KE; El-Agnaf OM
Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
[TBL] [Abstract][Full Text] [Related]
31. Implications of In Vitro Multi-Serine Phosphorylation of Alpha-Synuclein in Aggregation and Cytotoxicity.
Chaturvedi M; Raj R; Yadav SK; Srivastava T; Devi S; Dharmadana D; Valéry C; Sharma SK; Kumar D; Priya S
ACS Chem Neurosci; 2023 Sep; 14(17):3103-3112. PubMed ID: 37562012
[TBL] [Abstract][Full Text] [Related]
32. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
Levine PM; De Leon CA; Galesic A; Balana A; Marotta NP; Lewis YE; Pratt MR
Bioorg Med Chem; 2017 Sep; 25(18):4977-4982. PubMed ID: 28487126
[TBL] [Abstract][Full Text] [Related]
33. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
34. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
[TBL] [Abstract][Full Text] [Related]
35. Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications.
Pratt MR; Abeywardana T; Marotta NP
Biomolecules; 2015 Jun; 5(3):1210-27. PubMed ID: 26120904
[TBL] [Abstract][Full Text] [Related]
36. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
Brembati V; Faustini G; Longhena F; Bellucci A
Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556
[TBL] [Abstract][Full Text] [Related]
37. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
38. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
Javed H; Kamal MA; Ojha S
CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM.
Zhao K; Lim YJ; Liu Z; Long H; Sun Y; Hu JJ; Zhao C; Tao Y; Zhang X; Li D; Li YM; Liu C
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20305-20315. PubMed ID: 32737160
[TBL] [Abstract][Full Text] [Related]
40. What can trigger the onset of Parkinson's disease - A modeling study based on a compartmental model of α-synuclein transport and aggregation in neurons.
Kuznetsov IA; Kuznetsov AV
Math Biosci; 2016 Aug; 278():22-9. PubMed ID: 27211070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
